AWAdam R. Winstock

Adam R. Winstock

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Adam R. Winstock has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Reply

    by Katherine I. Morley, Jason Ferris, Adam R. Winstock, Michael T. Lynskey

  • Risk of emergency medical treatment following consumption of cannabis or synthetic cannabinoids in a large global sample

    by Adam Winstock, Michael Lynskey, Rohan Borschmann, Jon Waldron

    Synthetic cannabinoids (SCs) have become increasingly popular in recent years. Diverse in chemical structure, many have been subjected to legislative regulation, but their availability and use persists. Often marketed to reflect their similar effects to cannabis, their use has been associated with a range of negative health effects. We sought to determine the relative risk of seeking emergency medical treatment (EMT) following use of SCs and natural cannabis. We utilized an anonymous online survey of drug use, obtaining data from 22,289 respondents. We calculated the relative risk of seeking EMT between the two substances using an estimate for days used in the past year. Thirty-seven cannabis users (0.2%) and 21 SC users (1.0%) had sought EMT during the past year following use. The relative risk associated with the use of SCs was 30 (95% CI 17.5–51.2) times higher than that associated with cannabis. Significantly more symptoms (p=0.03) were reported by respondents seeking treatment for SCs than for cannabis. Whilst these findings must be treated with caution, SCs potentially pose a greater risk to users’ health than natural forms of cannabis. Regulation is unlikely to remove SCs from the market, so well-informed user-focused health promotion messages need to be crafted to discourage their use.


  • Dimethyltryptamine (DMT): Prevalence, user characteristics and abuse liability in a large global sample

    by Adam R Winstock, Stephen Kaar, Rohan Borschmann

    This paper presents original research on prevalence, user characteristics and effect profile of N,N-dimethyltryptamine (DMT), a potent hallucinogenic which acts primarily through the serotonergic system. Data were obtained from the Global Drug Survey (an anonymous online survey of people, many of whom have used drugs) conducted between November and December 2012 with 22,289 responses. Lifetime prevalence of DMT use was 8.9% (n=1980) and past year prevalence use was 5.0% (n=1123). We explored the effect profile of DMT in 472 participants who identified DMT as the last new drug they had tried for the first time and compared it with ratings provided by other respondents on psilocybin (magic mushrooms), LSD and ketamine. DMT was most often smoked and offered a strong, intense, short-lived psychedelic high with relatively few negative effects or “come down”. It had a larger proportion of new users compared with the other substances (24%), suggesting its popularity may increase. Overall, DMT seems to have a very desirable effect profile indicating a high abuse liability that maybe offset by a low urge to use more.


  • The 12‐month prevalence and nature of adverse experiences resulting in emergency medical presentations associated with the use of synthetic cannabinoid products

    by Adam R. Winstock, Monica J. Barratt

    Objective: A wide range of synthetic cannabinoid products have recently become available through the Internet and shop fronts across the globe. Concerns about the consequences of their use have been prompted by increasing reports of emergency department presentations.Methods: An anonymous global online survey was conducted using a research tool based on previous work carried out by the group. Data collection took place during a 4‐week period at the end of 2011.Results: Among 950 last‐year users, 23 (2.4%) reported having sought emergency medical treatment following the use of a synthetic cannabinoid product. The most common presentations were panic and anxiety, followed by paranoia and breathing difficulties. Recent users who reported seeking emergency medical treatment were significantly younger (median age 20 years, interquartile range 18–22) than those who did not report seeking treatment (median age 23 years, interquartile range 19–28; Mann–Whitney test, z = 2.89, p = 0.004).Conclusions: Synthetic cannabinoid use appears to be associated with a high prevalence of adverse experiences among users, especially younger users. Further research is required to determine whether particular compounds carry a higher risk of harm than others and to assess potential consequences of longer term use. Copyright © 2013 John Wiley & Sons, Ltd.


  • Hospital and prehospital emergency service utilisation as an impact of acute recreational drug and ethanol toxicity

    by J. R. H. Archer, P. I. Dargan, D. M. Wood, A. R. Winstock

    Background: Recreational drug use can cause significant acute toxicity and is typically associated with the utilisation of hospital/prehospital emergency medical services and health-care costs. Aims: To determine the impact of recreational drug toxicity on the utilisation of emergency medical services and subsequent drug use. Design and Methods: A total of 2472 UK participants completed an anonymous online cross-sectional questionnaire. The use of emergency medical services for acute recreational drug and/or ethanol toxicity and its impact on drug use were surveyed. Results: Four hundred and sixty-one (19%) had previously utilised emergency medical services following drugs/ethanol; of these, 57% (259) attended a hospital emergency department, out of which 59% (152) needed hospital admission. Forty-three percent (49 of 113 respondents) believed their most recent episode that required medical assistance was due to using “too much drug”. Forty-five percent (50 of 112 respondents) stated they would continue to use or increase their drug use. Ten percent (11) reported that the episode had resulted in them stopping use. Conclusions: A significant proportion of individuals used hospital/prehospital emergency services for acute toxicity after recreational drugs and/or ethanol use. This caused little impact on behaviour in relation to subsequent use. More work is needed to understand how to use these episodes to change patterns of drug and/or ethanol use.


  • Open Access

    Mephedrone: use, subjective effects and health risks

    by Adam Winstock, Luke Mitcheson, John Ramsey, Susannah Davies, Malgorzata Puchnarewicz, John Marsden

    Aims To assess the patterns of use, subjective effect profile and dependence liability of mephedrone, supported by corroborative urine toxicology. Design Cross-sectional structured telephone interview. Setting UK-based drug users associated with the dance music scene. Participants A total of 100 mephedrone users, recruited through their involvement with the dance music scene. Measurements Assessment of pattern of use, acute and after effects, DSM dependence criteria and gas chromatography-mass spectrometry urinalysis. Findings Mephedrone consumption results in typical stimulant-related subjective effects: euphoria, increased concentration, talkativeness, urge to move, empathy, jaw clenching, reduced appetite and insomnia. Thirty per cent of the sample potentially met criteria for DSM-IV dependence and there was evidence of a strong compulsion to use the drug (47% had used the drug for 2 or more consecutive days). Self-reported recent consumption of mephedrone was confirmed by toxicological analysis in all of the 14 participants who submitted a urine sample. Conclusion Mephedrone has a high abuse and health risk liability, with increased tolerance, impaired control and a compulsion to use, the predominant reported dependence symptoms.


  • Legal highs and the challenges for policy makers

    by Adam R. Winstock, John D. Ramsey


  • Mephedrone, new kid for the chop?

    by Adam R. Winstock, Luke R. Mitcheson, Paolo Deluca, Zoe Davey, Ornella Corazza, Fabrizio Schifano

    Aims Mephedrone (4-methylmethcathinone) is a novel synthetic stimulant drug that has recently become popular in the United Kingdom and elsewhere in Europe. It has a short history of human consumption and little is known about its prevalence and pattern of use. This study aimed to obtain preliminary data on its use and effects among dance drug users in the United Kingdom. Design Cross-sectional anonymous online survey of mephedrone recruited as part of larger study exploring patterns of drug use among those associated with the dance music scene. Setting UK-based dance music and clubbing website. Participants A total of 947 ever users of mephedrone recruited as part of a wider study on dance drug use patterns. Measurements Assessment of demographics, ever and current drug use and patterns and selected effects following use of mephedrone. Findings A total of 947 (41.3%) of 2295 participants reported ever having used mephedrone. Mephedrone was the sixth most frequently used drug in the last month after tobacco, alcohol, cannabis, cocaine and 3,4-methylenedioxymethamphetamine (MDMA). Users were typically younger (P < 0.001) and male (P < 0.01); 15.1% reported using weekly or more frequently; 49.5% reported using between 0.5 and 1 g during a typical session; 69.5% reported that intranasal use was the most common route of use. Intranasal use was associated with increased abuse liability; 54.6% of those who have also used cocaine reported that the quality of the high obtained with mephedrone was better, with those using intranasally being significantly more likely than those who took the drug orally to report that mephedrone was more addictive (P < 0.02) and more risky (P < 0.02) than cocaine. Route of use was unrelated to any stimulant-related adverse effect apart from palpitations (P < 0.005). Conclusions Mephedrone appears to be used primarily intranasally and to have comparable abuse potential to cocaine, with more than half those who use both reporting that mephedrone gives a better quality high.